Search

Background: We measured biomarkers of tumour growth and vascularity in interval and screen-detected colorectal cancers (CRCs) in the English Bowel Cancer Screening Programme in order to determine whether rapid tumour growth might contribute to interval CRC (a CRC diagnosed between a negative guaiac stool test and the next scheduled screening episode).Methods: Formalin-fixed, paraffin-embedded sections from 71 CRCs (screen-detected 43, interval 28) underwent immunohistochemistry for CD31 and Ki-67, in order to measure the microvessel density (MVD) and proliferation index (PI), respectively, as well as microsatellite instability (MSI) testing.Results: Interval CRCs were larger (P=0.02) and were more likely to exhibit venous invasion (P=0.005) than screen-detected tumours. There was no significant difference in MVD or PI between interval and screen-detected CRCs. More interval CRCs displayed MSI-high (14%) compared with screen-detected tumours (5%). A significantly (P=0.005) higher proportion (51%) of screen-detected CRC resection specimens contained at least one polyp compared with interval CRC (18%) resections.Conclusions: We found no evidence of biological differences between interval and screen-detected CRCs, consistent with the low sensitivity of guaiac stool testing as the main driver of interval CRC. The contribution of synchronous adenomas to occult blood loss for screening requires further investigation. [ABSTRACT FROM AUTHOR]

The article discusses the patterns of sexual transgression and gender in the web-based reality show "The Specials," which the publication "The Guardian" calls a docusoap. It states that the show is a story of white young adults who have intellectual disabilities and live together in Brighton, England. It says that web developer Daniel May and producer-director Katy Lock continued the series in 2009 even without institutional support and funding. It engages with the observation by writer Margrit Shildrick that interweaving of subjectivity, sexuality, and disability constitutes a risky combination. It mentions that the show was originally conceived as a television broadcast reality show.

We performed a systematic analysis of blood DNA methylation profiles from 4483 participants from seven independent cohorts identifying differentially methylated positions (DMPs) associated with psychosis, schizophrenia, and treatment-resistant schizophrenia. Psychosis cases were characterized by significant differences in measures of blood cell proportions and elevated smoking exposure derived from the DNA methylation data, with the largest differences seen in treatment-resistant schizophrenia patients. We implemented a stringent pipeline to meta-analyze epigenome-wide association study (EWAS) results across datasets, identifying 95 DMPs associated with psychosis and 1048 DMPs associated with schizophrenia, with evidence of colocalization to regions nominated by genetic association studies of disease. Many schizophrenia-associated DNA methylation differences were only present in patients with treatment-resistant schizophrenia, potentially reflecting exposure to the atypical antipsychotic clozapine. Our results highlight how DNA methylation data can be leveraged to identify physiological (e.g., differential cell counts) and environmental (e.g., smoking) factors associated with psychosis and molecular biomarkers of treatment-resistant schizophrenia., Competing Interests: EH, ED, GM, JB, NB, MB, AC, CC, DD, TD, GD, MG, AG, CG, HH, CH, VJ, RK, JK, GK, CM, AM, DM, KM, CM, IN, DQ, AR, BR, DS, ST, TT, JV, JW, EV, GB, LS, JM No competing interests declared, MD M Di Forti reports personal fees from Janssen, outside the submitted work. FG Fiona Gaughran has received honoraria from Lundbeck, Otsuka, and Sunovion. She has a family member with professional links to Lilly and GSK, including shares. KK Kaarina Kowalec has consulted with Emerald Lake Safety Ltd. (2017-2018) and has received speaker honoraria from Biogen/Fraser Health Multiple Sclerosis Clinic (2018). Both are unrelated to the work published here. JM James MacCabe has received research funding from H Lundbeck. MO Michael C O'Donovan is supported by a collaborative research grant from Takeda Pharmaceuticals. Takeda played no part in the conception, design, implementation, or interpretation of this study. PS PF Sullivan reports the following potentially competing financial interests. Current: Lundbeck (advisory committee, grant recipient). Past three years: Pfizer (scientific advisory board). DC David A Collier is a full time employee and stockholder of Eli Lilly and Company. RM Robin M Murray reports personal fees from Janssen, Lundbeck, Sunovion, Recordati and Otsuka, (© 2021, Hannon et al.)

Previously, we showed that 3% (31/1032)of asymptomatic healthcare workers (HCWs) from a large teaching hospital in Cambridge, UK, tested positive for SARS-CoV-2 in April 2020. About 15% (26/169) HCWs with symptoms of coronavirus disease 2019 (COVID-19) also tested positive for SARS-CoV-2 (Rivett et al., 2020). Here, we show that the proportion of both asymptomatic and symptomatic HCWs testing positive for SARS-CoV-2 rapidly declined to near-zero between 25th April and 24th May 2020, corresponding to a decline in patient admissions with COVID-19 during the ongoing UK 'lockdown'. These data demonstrate how infection prevention and control measures including staff testing may help prevent hospitals from becoming independent 'hubs' of SARS-CoV-2 transmission, and illustrate how, with appropriate precautions, organizations in other sectors may be able to resume on-site work safely., Competing Interests: NJ, LR, DS, SF, SS, JY, JP, CC, HG, NR, MW, MR, BW, JL, WC, FS, CM, MF, JG, MG, MC, SF, AS, JB, GH, GW No competing interests declared, AC Afzal Chaudhry reports grants from Cambridge Biomedical Research Centre at CUHNFT, during the conduct of the study. IG Ian Goodfellow reports grants from Wellcome Trust (Senior Research Fellowships), grants from Wellcome Trust (Collaborative Award), grants from Addenbrooke's Charitable Trust, during the conduct of the study. GD Gordon Dougan reports grants from NIHR, during the conduct of the study. KS Kenneth GC Smith reports grants from Wellcome Trust, during the conduct of the study. PL Paul J Lehner reports grants from Wellcome Trust Principal Research Fellowship, grants from Addenbrooke's Charitable Trust, during the conduct of the study. NM Nicholas J Matheson reports grants from Medical Research Council (Clinician Scientist Fellowship), grants from NHS Blood and Transfusion, during the conduct of the study. SB Stephen Baker reports grants from Wellcome Trust (Senior Research Fellowships), from Addenbrooke's Charitable Trust, during the conduct of the study. MW Michael P Weekes reports grants from Wellcome Trust (Senior Research Fellowships), from Addenbrooke's Charitable Trust, during the conduct of the study., (© 2020, Jones et al.)